Lung Cancer Screening Market Size, Competitive Landscape Forecasts to 2028

According to Precision Business Insights (PBI), the latest report the global lung cancer screening market is expected to be worth USD 1,768.1 million in 2021 and projected to grow at a 6.5% CAGR over 2022 to 2028. One of the primary reasons driving the growth of the lung cancer screening market is the rise in the adoption of unhealthy lifestyles such as smoking. Cigarette smoking is a well-known cause of lung cancer. The growth in government programmes and other private groups promoting early cancer detection and prevention has a further impact on the industry.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/lung-cancer-screening-market/

The Non-Small Cell Lung Cancer Segment is Dominating the Lung Cancer Screening Market:
NSCLC accounts for a significant percentage of lung cancer occurrences globally, and this high number has motivated market participants to focus on the discovery of novel treatments and the improvement of the efficacy of current drugs for the condition. Lung cancer is one of the most frequent cancers, accounting for a considerable number of deaths worldwide. As a result, there is a greater need to treat the condition and lower the death rate. Expansion of NSCLC market is further aided by an increase in frequency of diagnosis of non-small cell lung cancer and increased awareness regarding the disease in developed and emerging countries.

North America Leads Lung Cancer Screening Market:
North America is expected to hold significant market share in the global Lung Cancer Screening Market and is projected to grow at a prominent growth rate over the forecast years owing to rapid growth This is because of the prevailing sophisticated level of healthcare facilities, on-going strategic partnerships, and the presence of major key players in the region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period owing to the rising cases of lung cancer and increased expenditure on healthcare infrastructure.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=64857

The lung cancer screening market is segmented based on by cancer type, by diagnosis type, end-users, and geography.
Based on the Cancer Type:
• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer

Based on the Diagnosis Type:
• Low Dose Spiral CT scan
• Chest X-Ray

Based on the End-Users:
• Hospital & Clinics
• Diagnostic Centers

Request methodology: https://precisionbusinessinsights.com/request-methodology?product_id=64857

Key player's profiles in the lung cancer screening market report are PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmbH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company. Epic Systems Corporation, Lungview, Eon, Medtronic, HealthMyne, Oncocyte Corporation, Genesystem, FUJIFILM Holdings Corporation, Median Technologies, AstraZeneca.

Contact:
Mr. Satya
Precision Business Insights | Toll-Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.